Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track SNDX with free AI briefings, catalyst countdowns, and dilution alerts.

SNDX · Syndax Pharmaceuticals Inc

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$551.1M Cash on Hand
57.5mo Cash Runway
21.4% Short Interest
$35.45 Analyst Target (11)
Follow SNDX by email Get an email when SNDX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SNDX, unsubscribe in one click. Privacy

📣 What SNDX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Revumenib (SNDX-5613)
FDA approved Nov 2024 · Revuforj
Acute Myeloid Leukemias Phase 3 · NCT07211958 Recruiting
Axatilimab (SNDX-6352)
FDA approved Aug 2024 · Niktimvo
Chronic Graft-versus-host-disease Phase 2 · NCT04710576 Recruiting
Gilteritinib Previously Untreated Relapsed Refractory Acute Myeloid Leukemia Phase 2/3 · NCT03013998 Recruiting
Daunorubicin Previously Untreated Relapsed Refractory Acute Myeloid Leukemia Phase 2/3 · NCT03013998 Recruiting
Daunorubicin or Idarubicin (BAML-16-001-S25/HO18… Previously Untreated Relapsed Refractory Acute Myeloid Leukemia Phase 2/3 · NCT03013998 Recruiting
Ivosidenib (AG-120) Previously Untreated Relapsed Refractory Acute Myeloid Leukemia Phase 2/3 · NCT03013998 Recruiting
Entospletinib Previously Untreated Relapsed Refractory Acute Myeloid Leukemia Phase 2/3 · NCT03013998 Recruiting
Ficlatuzumab Previously Untreated Relapsed Refractory Acute Myeloid Leukemia Phase 2/3 · NCT03013998 Recruiting
Intensive Chemotherapy Regimen Acute Myeloid Leukemias Phase 3 · NCT07211958 Recruiting
Pevonedistat Previously Untreated Relapsed Refractory Acute Myeloid Leukemia Phase 2/3 · NCT03013998 Recruiting
Samalizumab Previously Untreated Relapsed Refractory Acute Myeloid Leukemia Phase 2/3 · NCT03013998 Recruiting
Dubermatinib (TP-0903) Previously Untreated Relapsed Refractory Acute Myeloid Leukemia Phase 2/3 · NCT03013998 Recruiting
Lomonitinib Previously Untreated Relapsed Refractory Acute Myeloid Leukemia Phase 2/3 · NCT03013998 Recruiting
Enasidenib (AG-221) Previously Untreated Relapsed Refractory Acute Myeloid Leukemia Phase 2/3 · NCT03013998 Recruiting
Bivalent BRD4 Inhibitor AZD5153 Previously Untreated Relapsed Refractory Acute Myeloid Leukemia Phase 2/3 · NCT03013998 Recruiting
Mcl-1 Inhibitor AZD5991 Previously Untreated Relapsed Refractory Acute Myeloid Leukemia Phase 2/3 · NCT03013998 Recruiting

Also used in these trials (approved or third-party drugs, not SNDX's own candidates): Cytarabine, Decitabine, Venetoclax, Azacitidine, Avelumab, Momelotinib, Nivolumab, Pembrolizumab, Cobicistat, Anastrozole, Atezolizumab, Ruxolitinib.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

SNDX holds $551.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $28.8M/quarter from operations, an estimated runway of 57.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 25 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SNDX files for a raise →

👥 Who Owns SNDX

Insiders 1.8% Institutions (340 holders) 98.2% Public and other holders 0%
HolderTypeShares% of sharesAs of
Blackrock Inc. Institution (13F) 9,268,460 10.38% 2026-09-30
Kynam Capital Management, LP Institution (13F) 8,150,959 9.13% 2026-09-30
Goldman Sachs Group Inc Institution (13F) 5,523,284 6.19% 2026-09-30
STATE STREET CORPORATION Institution (13G, 5%+) 4,653,172 5.21% 2026-09-30
Vanguard Capital Management Institution (13G, 5%+) 4,457,143 4.99% 2026-03-31
Bank of America Corporation Institution (13F) 3,801,955 4.26% 2026-09-30
Deerfield Management Company, L.P Institution (13F) 3,779,900 4.23% 2026-09-30
Franklin Resources, Inc. Institution (13F) 3,485,448 3.90% 2026-09-30
Franklin Templeton, Inc. Institution (13F) 3,485,448 3.90% 2026-09-30
Hood River Capital Management LLC Institution (13F) 2,596,543 2.91% 2026-09-30
Eversept Partners, LP Institution (13F) 2,443,056 2.74% 2026-09-30
Michael A Metzger
Chief Executive Officer, Director · +804,000 options
Insider 484,843 0.54% 2026-07-08

Share count 89,297,086 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-09
filed 2026-11-12
Ondrey Aaron
Option award (A) 270,000 $9.55 –
2026-10-29
filed 2026-10-30
Podlesak Dennis
Option exercise (M) 8,000 $11.81 247,763
2026-10-29
filed 2026-10-30
Podlesak Dennis
Sale (S) 8,000 $14.21 239,763
2026-10-29
filed 2026-10-30
Podlesak Dennis
Option exercise (M) 8,000 – –
2026-07-08
filed 2026-07-09
Metzger Michael A
Sale (S) 32,375 $24.24 484,843

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2025-10-25 Revuforj sNDA -10% -3.1% +1.3%

Browse all historical PDUFA outcomes →

Get the full SNDX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SNDX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.